Gene therapy using a liver-targeted AAV vector restores nucleoside and nucleotide homeostasis in a murine model of MNGIE

Javier Torres-Torronteras, Carlo Viscomi, Raquel Cabrera-Pérez, Yolanda Cámara, Ivano Di Meo, Jordi Barquinero, Alberto Auricchio, Giuseppe Pizzorno, Michio Hirano, Massimo Zeviani, Ramon Martí

Research output: Contribution to journalArticle

Abstract

Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive disorder caused by mutations in TYMP, enconding thymidine phosphorylase (TP). TP deficiency results in systemic accumulation of thymidine and deoxyuridine, which interferes with mitochondrial DNA (mtDNA) replication and leads to mitochondrial dysfunction. To date, the only treatment available for MNGIE patients is allogeneic hematopoietic stem cell transplantation, which is associated with high morbidity and mortality. Here, we report that AAV2/8-mediated transfer of the human TYMP coding sequence (hcTYMP) under the control of a liver-specific promoter prevents the biochemical imbalances in a murine model of MNGIE. hcTYMP expression was restricted to liver, and a dose as low as 2 × 10 11 genome copies/kg led to a permanent reduction in systemic nucleoside levels to normal values in about 50% of treated mice. Higher doses resulted in reductions to normal or slightly below normal levels in virtually all mice treated. The nucleoside reduction achieved by this treatment prevented deoxycytidine triphosphate (dCTP) depletion, which is the limiting factor affecting mtDNA replication in this disease. These results demonstrate that the use of AAV to direct TYMP expression in liver is feasible as a potentially safe gene therapy strategy for MNGIE.

Original languageEnglish
Pages (from-to)901-907
Number of pages7
JournalMolecular Therapy
Volume22
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Mitochondrial Encephalomyopathies
Nucleosides
Genetic Therapy
Homeostasis
Nucleotides
Liver
DNA Replication
Mitochondrial DNA
Thymidine Phosphorylase
Deoxyuridine
Hematopoietic Stem Cell Transplantation
Thymidine
Reference Values
Genome
Morbidity
Mutation
Mortality
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology
  • Medicine(all)

Cite this

Torres-Torronteras, J., Viscomi, C., Cabrera-Pérez, R., Cámara, Y., Di Meo, I., Barquinero, J., ... Martí, R. (2014). Gene therapy using a liver-targeted AAV vector restores nucleoside and nucleotide homeostasis in a murine model of MNGIE. Molecular Therapy, 22(5), 901-907. https://doi.org/10.1038/mt.2014.6

Gene therapy using a liver-targeted AAV vector restores nucleoside and nucleotide homeostasis in a murine model of MNGIE. / Torres-Torronteras, Javier; Viscomi, Carlo; Cabrera-Pérez, Raquel; Cámara, Yolanda; Di Meo, Ivano; Barquinero, Jordi; Auricchio, Alberto; Pizzorno, Giuseppe; Hirano, Michio; Zeviani, Massimo; Martí, Ramon.

In: Molecular Therapy, Vol. 22, No. 5, 2014, p. 901-907.

Research output: Contribution to journalArticle

Torres-Torronteras, J, Viscomi, C, Cabrera-Pérez, R, Cámara, Y, Di Meo, I, Barquinero, J, Auricchio, A, Pizzorno, G, Hirano, M, Zeviani, M & Martí, R 2014, 'Gene therapy using a liver-targeted AAV vector restores nucleoside and nucleotide homeostasis in a murine model of MNGIE', Molecular Therapy, vol. 22, no. 5, pp. 901-907. https://doi.org/10.1038/mt.2014.6
Torres-Torronteras J, Viscomi C, Cabrera-Pérez R, Cámara Y, Di Meo I, Barquinero J et al. Gene therapy using a liver-targeted AAV vector restores nucleoside and nucleotide homeostasis in a murine model of MNGIE. Molecular Therapy. 2014;22(5):901-907. https://doi.org/10.1038/mt.2014.6
Torres-Torronteras, Javier ; Viscomi, Carlo ; Cabrera-Pérez, Raquel ; Cámara, Yolanda ; Di Meo, Ivano ; Barquinero, Jordi ; Auricchio, Alberto ; Pizzorno, Giuseppe ; Hirano, Michio ; Zeviani, Massimo ; Martí, Ramon. / Gene therapy using a liver-targeted AAV vector restores nucleoside and nucleotide homeostasis in a murine model of MNGIE. In: Molecular Therapy. 2014 ; Vol. 22, No. 5. pp. 901-907.
@article{96b0f66e76a24b678c9504ecb1159f57,
title = "Gene therapy using a liver-targeted AAV vector restores nucleoside and nucleotide homeostasis in a murine model of MNGIE",
abstract = "Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive disorder caused by mutations in TYMP, enconding thymidine phosphorylase (TP). TP deficiency results in systemic accumulation of thymidine and deoxyuridine, which interferes with mitochondrial DNA (mtDNA) replication and leads to mitochondrial dysfunction. To date, the only treatment available for MNGIE patients is allogeneic hematopoietic stem cell transplantation, which is associated with high morbidity and mortality. Here, we report that AAV2/8-mediated transfer of the human TYMP coding sequence (hcTYMP) under the control of a liver-specific promoter prevents the biochemical imbalances in a murine model of MNGIE. hcTYMP expression was restricted to liver, and a dose as low as 2 × 10 11 genome copies/kg led to a permanent reduction in systemic nucleoside levels to normal values in about 50{\%} of treated mice. Higher doses resulted in reductions to normal or slightly below normal levels in virtually all mice treated. The nucleoside reduction achieved by this treatment prevented deoxycytidine triphosphate (dCTP) depletion, which is the limiting factor affecting mtDNA replication in this disease. These results demonstrate that the use of AAV to direct TYMP expression in liver is feasible as a potentially safe gene therapy strategy for MNGIE.",
author = "Javier Torres-Torronteras and Carlo Viscomi and Raquel Cabrera-P{\'e}rez and Yolanda C{\'a}mara and {Di Meo}, Ivano and Jordi Barquinero and Alberto Auricchio and Giuseppe Pizzorno and Michio Hirano and Massimo Zeviani and Ramon Mart{\'i}",
year = "2014",
doi = "10.1038/mt.2014.6",
language = "English",
volume = "22",
pages = "901--907",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Gene therapy using a liver-targeted AAV vector restores nucleoside and nucleotide homeostasis in a murine model of MNGIE

AU - Torres-Torronteras, Javier

AU - Viscomi, Carlo

AU - Cabrera-Pérez, Raquel

AU - Cámara, Yolanda

AU - Di Meo, Ivano

AU - Barquinero, Jordi

AU - Auricchio, Alberto

AU - Pizzorno, Giuseppe

AU - Hirano, Michio

AU - Zeviani, Massimo

AU - Martí, Ramon

PY - 2014

Y1 - 2014

N2 - Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive disorder caused by mutations in TYMP, enconding thymidine phosphorylase (TP). TP deficiency results in systemic accumulation of thymidine and deoxyuridine, which interferes with mitochondrial DNA (mtDNA) replication and leads to mitochondrial dysfunction. To date, the only treatment available for MNGIE patients is allogeneic hematopoietic stem cell transplantation, which is associated with high morbidity and mortality. Here, we report that AAV2/8-mediated transfer of the human TYMP coding sequence (hcTYMP) under the control of a liver-specific promoter prevents the biochemical imbalances in a murine model of MNGIE. hcTYMP expression was restricted to liver, and a dose as low as 2 × 10 11 genome copies/kg led to a permanent reduction in systemic nucleoside levels to normal values in about 50% of treated mice. Higher doses resulted in reductions to normal or slightly below normal levels in virtually all mice treated. The nucleoside reduction achieved by this treatment prevented deoxycytidine triphosphate (dCTP) depletion, which is the limiting factor affecting mtDNA replication in this disease. These results demonstrate that the use of AAV to direct TYMP expression in liver is feasible as a potentially safe gene therapy strategy for MNGIE.

AB - Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive disorder caused by mutations in TYMP, enconding thymidine phosphorylase (TP). TP deficiency results in systemic accumulation of thymidine and deoxyuridine, which interferes with mitochondrial DNA (mtDNA) replication and leads to mitochondrial dysfunction. To date, the only treatment available for MNGIE patients is allogeneic hematopoietic stem cell transplantation, which is associated with high morbidity and mortality. Here, we report that AAV2/8-mediated transfer of the human TYMP coding sequence (hcTYMP) under the control of a liver-specific promoter prevents the biochemical imbalances in a murine model of MNGIE. hcTYMP expression was restricted to liver, and a dose as low as 2 × 10 11 genome copies/kg led to a permanent reduction in systemic nucleoside levels to normal values in about 50% of treated mice. Higher doses resulted in reductions to normal or slightly below normal levels in virtually all mice treated. The nucleoside reduction achieved by this treatment prevented deoxycytidine triphosphate (dCTP) depletion, which is the limiting factor affecting mtDNA replication in this disease. These results demonstrate that the use of AAV to direct TYMP expression in liver is feasible as a potentially safe gene therapy strategy for MNGIE.

UR - http://www.scopus.com/inward/record.url?scp=84899994577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899994577&partnerID=8YFLogxK

U2 - 10.1038/mt.2014.6

DO - 10.1038/mt.2014.6

M3 - Article

C2 - 24448160

AN - SCOPUS:84899994577

VL - 22

SP - 901

EP - 907

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 5

ER -